TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02158598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D pill supplementation
Study: NCT02995889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLT-PET
Study: NCT04517539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF，Peginterferon alfa-b2，radiation
Description: Radiation:~If there are two measurable lesions totally, One lesion received radiotherapy for 30 Gy in 5 fractions and rested for one week; If there are three measurable lesions totally, two lesion received radiotherapy for 30 Gy in 5 fractions separately.~drug: Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy. Peginterferon alfa-b2 90 ug in d8 in each cycle.~And the 1 month after the end of all radiotherapy courses, 4 weeks as a course of treatment, once per course of treatment, each dose is 90μg until desease progress.
Study: NCT02403947

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suspension media
Description: injection suspension media
Study: NCT00708669

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS stent
Description: Compared two kinds of stents:TAXUS stent, approved for commercialization in Japan(March 30th, 2007)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher stent
Description: CYPHER stent, approved for commercialization in Japan(March 25, 2004)
Study: NCT01356810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Intervention
Description: The environmental intervention consisted of daily reorientation, avoidance of sensorial deprivation, longer visiting hours, the availability of a clock, a calendar and the presence of familiar objects in the room.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Delirium management by the attending physician's preferences.
Study: NCT02219204

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Study: NCT00781794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSA-789 at 2 different doses
Study: NCT00463437

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: Intramuscular injection, 1 dose.
Study: NCT02219204

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Herbal treatment
Study: NCT01479530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily; tablet; orally; 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilect®
Description: 1 mg daily; tablet; orally; 16 weeks
Study: NCT00463437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 1 dose. In Germany and Poland.
Study: NCT03061019

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Myofunctional Therapy with exercices
Description: Oral-Motor training of oral muscles (tongue, lips) associated with nasal hygiene with daily repetition of exercices and parental support.
Study: NCT00781794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSA-789 at 2 different doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NSA-789 at 2 different doses
Study: NCT02479633

Intervention type: OTHER
Group type: OTHER
Intervention: Coronally advanced flap with connective tissue graft
Description: Two oblique, divergent releasing incisions extending beyond the mucogingival junction were performed. An intra-sulcular incision was performed at the buccal aspect of the involved tooth. Subsequently, a partial-thickness flap was raised beyond the MGJ. The papilla adjacent to the involved tooth were then de-epithelialized.~The CTG was harvested using a single incision approach from the palate. The graft was positioned on the instrumented root surface immediately apical of the CEJ and then stabilized using a sling compressive crossing suture. The flap was coronally displaced 1-2 mm above the CEJ. A sling suture was placed to stabilize the flap in a coronal position, followed by interrupted sutures on the releasing incisions with an apico-coronal direction.
Study: NCT00463437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 1 dose. In Germany and Poland.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix IPV Hib
Description: Intramuscular injection, 1 dose. In Spain.
Study: NCT03061019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Myofunctional Therapy with soft oral appliance
Description: Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
Study: NCT02271802

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium butyrate
Description: Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study: NCT00514527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oritavancin
Description: Oritavancin as a single, infrequent or daily dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oritavancin
Description: Oritavancin as a single, infrequent or daily dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oritavancin
Description: Oritavancin as a single, infrequent or daily dose.
Study: NCT04071886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Training
Description: Mindfulness-Based Training comprises of mindful walking, body scanning and raisin meditation exercise. Participants will receive a guided session of mindfulness meditation, and will be asked to finish at least 30 minutes of Mindfulness-Based Training every day as homework as well as keep a diary describing their experiences and reflections. An expert in mindfulness practice will offer feedback and answer any questions online.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Participants will listen to a 15-minute Relaxation Training tape twice a day.
Study: NCT01995435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine refraction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine refraction
Study: NCT04024163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: Drug: Benznidazole Tablets 100 mg (functionally scored) or Tablets 12.5 mg
Study: NCT03769896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nabilone 0.25 mg
Description: capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
Study: NCT01995435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional refraction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional refraction
Study: NCT03185507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoHelmet
Description: Cryotherapy was administered using the Catalyst CryoHelmet™ (All-Star Sporting Goods®, Shirley, Massachusetts, USA). The CyroHelmet is a flexible helmet equipped with gel ice packs meant to cool the head and neck.
Study: NCT02830633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LNTME
Description: Patients in this group received laparoscopy-assisted nerve-preserved TME for treatment of rectal cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OTME
Description: Patients in this group received traditional open TME for treatment of rectal cancer
Study: NCT02710747

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C9;VKORC1
Study: NCT03469674

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal brachytherapy
Description: Internal radiation of the vaginal vault using a vaginal cylinder, 21 Gy in 3 out-patient sessions over 2 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: External beam pelvic radiotherapy on a linear accelerator, 48.6 Gy in 27 out-patients sessions over 5.5 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: No radiation therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
Study: NCT00463437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix IPV Hib
Description: Intramuscular injection, 1 dose. In Spain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix penta
Description: Intramuscular injection, 1 dose. In Germany and Poland.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix penta
Description: Intramuscular injection, 1 dose. In Germany and Poland.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix IPV
Description: Intramuscular injection, 1 dose. In Spain.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix IPV
Description: Intramuscular injection, 1 dose. In Spain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningitec
Description: Intramuscular injection, 1 dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac-C
Description: Intramuscular injection, 1 dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menitorix
Description: Intramuscular injection, 1 dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menitorix
Description: Intramuscular injection, 1 dose.
Study: NCT02715648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Study: NCT02256358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: preoperatively injected intravenous 0.1 mg/kg midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Preoperatively injected intravenous 1mg/kg ketamine
Study: NCT04432428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Sublingual Tablet
Description: all patients will receive tablets for sublingual use, containing 15 microgram of sufentanil. The sufentanil tablets come in a cartridge (40 tablets) and are administered with a special patient-controlled device that uses thumb tag recognition.~max dose per hour : 3 tablets of 15µg sufentanil
Study: NCT01815684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral
Study: NCT00263939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homing in on Health
Description: A peer (non-health professional) delivered intervention to enhance patient self-efficacy for chronic disease self-management. Developed as a modification of the Stanford Chronic Disease Self-Management Program.
Study: NCT00585650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injections
Description: Placebo injections twice weekly for 12 weeks.
Study: NCT00604383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruboxistaurin
Description: 32-mg tablet, orally, daily, up to 42 months
Study: NCT01815684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT03114969

Intervention type: DEVICE
Intervention: Relvar ELLIPTA
Description: ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Relvar ELLIPTA
Description: ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Symbicort TURBUHALER
Description: TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Symbicort TURBUHALER
Description: TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Seretide DISKUS
Description: DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Seretide DISKUS
Description: DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Spiriva HANDIHALER
Description: HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Spiriva HANDIHALER
Description: HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Spiriva HANDIHALER
Description: HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Spiriva HANDIHALER
Description: HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: BREEZHALER
Description: BREEZHALER inhaler containing either Seebri or Ultibro will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Incruse ELLIPTA
Description: ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Incruse ELLIPTA
Description: ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Incruse ELLIPTA
Description: ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Incruse ELLIPTA
Description: ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.

Intervention type: DEVICE
Intervention: Anoro ELLIPTA
Description: ELLIPTA inhaler containing Anoro will be used by subjects as their maintenance treatment to control COPD.
Study: NCT00519623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PassPort(R) Transdermal Insulin Delivery System
Description: The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.
Study: NCT01824602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1800 mg
Description: Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg
Description: Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 600 mg
Description: Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Study: NCT00604383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet, orally, daily, up to 42 months
Study: NCT00997126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
Study: NCT01824602

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pills
Study: NCT05042245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ornithine aspartate granule
Description: Ornithine aspartate granules in the experimental arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silymarin capsule
Description: Silymarin capsules in the active comparator arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin capsule simulant
Description: Silymarin capsule simulant in the experimental arm.
Study: NCT03769896

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, corn starch, daily basis
Study: NCT04354493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myo-electric Gaming Interface
Description: Non-significant risk, video game controller which maps myo-electric control signals to button presses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myo-electric Gaming Interface
Description: Non-significant risk, video game controller which maps myo-electric control signals to button presses.
Study: NCT04548635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-PAT
Description: Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
Study: NCT03199872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV001V
Description: Sc injection
Study: NCT01312844

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine
Description: Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
Study: NCT04270786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early de-escalation
Description: In de-escalating group, the empirical antibiotics will be stopped and then prophylaxis levofloxacin will be resumed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard
Description: In the control arm, empirical antibiotics will be continue until recpvery of neutropenia or at least 7 days after afebrile.
Study: NCT01312844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
Study: NCT02476994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinolipid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: Standard-of-Care Soybean Oil-Based Lipid Emulsion
Study: NCT02256683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
Study: NCT03037554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleepwear with Lateralized Thermal Characteristics
Description: Subjects will wear sleepwear constructed with insulating fabric on one side and conductive fabric on the other side, arranged bilaterally.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-Lateralized Sleepwear
Description: Subjects will wear sleepwear constructed with two insulating fabrics arranged bilaterally.
Study: NCT02907983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stellate Ganglion Block Injection with Bupivicaine
Description: A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline injection
Description: A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
Study: NCT04510545

Intervention type: DIAGNOSTIC_TEST
Intervention: Endobrain, Computer Aided Diagnosis (CAD)
Description: Artificial intelligence
Study: NCT01621945

Intervention type: BIOLOGICAL
Intervention: MenBvac
Description: Blood test
Study: NCT03676764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
Study: NCT01769365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-day quadruple therapy
Description: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy
Description: pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7-day standard triple therapy
Description: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
Study: NCT01641783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle Albumin-Bound paclitaxel
Description: nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
Study: NCT00520442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetamin w codeine
Study: NCT02372084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osilodrostat
Study: NCT01272895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Intervention (GENOUS stent)
Description: GENOUS stent (Coronary Intervention)